Your session is about to expire
← Back to Search
Selinexor for Myelofibrosis
Study Summary
This trial is testing a new drug, selinexor, to see if it is better than the current standard of care for myelofibrosis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 116 Patients • NCT02025985Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a man who will use effective birth control during and for 3 months after the study, and won't donate sperm.My spleen is enlarged, measuring over 450 cm^3 on an MRI or CT scan.I have hepatitis C but my viral load is undetectable.I am a woman who can have children, not pregnant, and will use birth control during and after the study.My kidneys are functioning well enough for treatment.I am able to get out of my bed or chair and move around.I do not have severe GI issues that could affect medication absorption.I have HIV with a CD4 count ≥350, undetectable viral load, and no recent AIDS-related infections.I have hepatitis B but have been on antiviral therapy for over 8 weeks and my viral load is under 100 IU/mL.My condition worsened or didn't improve significantly on JAK inhibitors.I have hepatitis B but have been on antiviral therapy for over 8 weeks and my viral load is under 100 IU/mL.I have HIV with a CD4 count ≥350, undetectable viral load, and no recent AIDS-related infections.I have been diagnosed with a specific type of blood cancer (MF, post-ET MF, or post-PV MF) as per WHO guidelines.I am not pregnant, can use birth control during the study, and am under 50 or cannot have children.I am a man who will use effective birth control during and for 3 months after the study.I haven't taken any standard or experimental treatments for myelofibrosis in the last 21 days, except for hydroxyurea or growth factors.I am 18 years old or older.I have been treated with JAK inhibitors for at least 6 months.I haven't taken strong CYP3A affecting drugs within the last week.I haven't needed strong IV drugs for an infection in the last week.I have hepatitis C but my viral load is undetectable.I am 18 years old or older.I have not had major surgery in the last 4 weeks.I have been diagnosed with a specific type of blood cancer according to the latest WHO guidelines.I can take care of myself and am up and about more than 50% of my waking hours.My blood or bone marrow has a high number of immature cells.I am not pregnant or breastfeeding.I am not allergic or unable to take selinexor or the drugs in the study.I have been treated with selinexor or similar drugs before.My spleen is enlarged, measuring over 450 cm^3 on an MRI or CT scan.I have been treated with JAK inhibitors for at least 6 months.
- Group 1: Arm PC: Physician's Choice Treatment
- Group 2: Arm S: Selinexor
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what regions is this experiment accessible?
"At this moment in time, 10 different clinical sites are hosting the trial. These include Fairfax and Tyler as well as 8 other cities. To minimize travel demands, it is suggested to choose the closest location to join."
Would this be considered a pioneering trial?
"Since its initial study, sponsored by Karyopharm Therapeutics Inc., in 2014 (involving 16 patients), Selinexor has received Phase 1 approval and is now being studied as part of 48 different live trials across 259 locations spanning 28 nations."
Are researchers currently looking to enroll participants in this experiment?
"According to the clinicaltrials.gov page, this trial is still recruiting participants. This research program was initially posted on 17th March 2021 and underwent its most recent edit on 15th November 2022."
What risks may be associated with utilizing Selinexor therapeutically?
"Our internal assessment of Selinexor's safety was a 2 due to Phase 2 trial data, which reveals some evidence of the drug's security but no proof of its efficacy."
Are there any precedents for the use of Selinexor in clinical trials?
"At this moment, 48 clinical trials are running for Selinexor. Out of those studies, 4 have reached Phase 3. In total, 922 sites across the world are conducting research on these treatments; however, most of them are based in Bethesda MD."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger